Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | FPR2 | P25090 | 3/20 | 0.56 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408063 | 0.99 | KMT2A (0.67) | KMT2AMAPK1L3MBTL1CTSSCTSL | |
| SCHEMBL4900321 | 0.99 | KMT2A (0.67) | KMT2AMAPK1L3MBTL1CTSSCTSL | |
| SCHEMBL7544578 | 0.93 | CTSS (0.61) | KMT2AMAPK1L3MBTL1CTSSCTSL | |
| SCHEMBL3052482 | 0.90 | KMT2A (0.60) | KMT2AMAPK1L3MBTL1CTSSCTSL | |
| SCHEMBL23056421 | 0.89 | KMT2A (0.54) | KMT2AMAPK1L3MBTL1CTSSCTSL | |
| SCHEMBL13291363 | 0.89 | KMT2A (0.64) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL27340724 | 0.89 | KMT2A (0.64) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL5444581 | 0.88 | CTSK (0.59) | KMT2AMAPK1L3MBTL1CTSSCTSL | |
| SCHEMBL6165862 | 0.88 | KMT2A (0.63) | KMT2AMAPK1CTSSCTSLCTSB | |
| SCHEMBL29165165 | 0.88 | KMT2A (0.63) | KMT2AMAPK1CTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960575-B2 | For use as inhibitors of chymase | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-01 | — | — | US | disclosed |
| US-20040097496-A1 | Novel thiazine derivatives | SANTEN PHARMACEUTICAL CO.,LTD. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-6713472-B1 | 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| EP-1211249-A1 | NOVEL THIAZINE OR PYRAZINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097496-A1 | Novel thiazine derivatives | CMA1, TPSD1, HRH4 | KMT2A 3612/4885MAPK1 1073/4885L3MBTL1 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.